Chantix Home Buy Chantix Chantix Home

Chantix News



News 2010
June 2010 September 2010  
Archives
January 2009 February 2009 March 2009
April 2009 May 2009 June 2009
July 2009 August 2009 September 2009
November 2009 December 2009  
Archives 2008 Archives 2007 Archives 2006

Study Establishes The Efficacy Of Nicotine Patches In Assisting Coronary Artery Disease Patients To Quit Smoking

March 28, 2007

In a recent experiment headed by Craig Pratt, cardiologist and director of Research at The Methodist DeBakey Heart Center, The Methodist Hospital, Houston, nicotine patches were found to be safe and effective for patients with coronary artery disease (CAD) in inducing smoking cessation . The results derived from the study were presented at the American College of Cardiology's 56th Annual Scientific Session where 30,000 cardiovascular experts were assembled.

In the experiment, the CAD afflicted patients who had more than nine percent ischemic perfusion defect size (PDS, a measure of the amount of reduction in myocardial tissue blood flow) were selected and the effects of nicotine patches on stress-induced myocardial ischemia was measured by the utilization of single photon emission computed tomography (SPECT). Alongside, the smokers who took more than 20 cigarettes were either given 21mg NicoDerm ® CQ® nicotine patches or placebo patches and after the completion of one week SPECT scan on patients was repeated and they were told to curb on their nicotine cravings by using the nicotine patch at the same time.

On the fourth week, a similar SPECT scan was conducted on patients and it became evident that in comparison to the patients who were provided the placebo patches, the active patch group showing an increase in nicotine levels and notwithstanding the nicotine increase, no specific changes in total or ischemic PDS were observed from baseline.

Before conducting each SPECT scan, the researchers measured the carbon monoxide levels and when they made a comparison between the results derived from the active patch using patients and the patients administered with placebo, the reduction of carbon monoxide was found to be significantly higher in active patch users (22.3 vs. 11.5 parts per million, or ppm ) in comparison to the placebo users(23 vs. 18.6 ppm).

Dr Craig Pratt pronounces that these clinical findings demonstrating the effects of Nicotine Replacement Therapy (NRT) are very important as these results are expected to play a significant role in reassuring smokers and physicians regarding the safety and efficacy of replacement therapy (NRT) in patients with CAD.

Source: http://www.webwire.com


Other News on Chantix:
Smoking Addiction By Pregnant Women Places their Children At Risk Of Heart Diseases
Chantix Helps Nurse To Quit Smoking
Researchers Figure Out Factors Responsible For Nicotine Cravings In Smokers
Research Evaluates Chantix As More Effective Than Zyban
Employees At Sandia National Laboratories Quit Smoking With the Help Of Chantix
Back to News
 
Home | About chantix | Chantix Working | Chantix Precautions | Chantix Dosage & Usage | Chantix Storage | Chantix Side Effects
© copyright reserved (http://www.chantixhome.com) 2010 Disclaimer | Resources | Contact
Home Bookmark Chantixhome.com Sitemap